Drug intelligence / Profile preview

alpha-asarone

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral
01

Overview

Alpha-asarone is a naturally occurring phenylpropanoid small molecule extracted from the rhizomes of *Acorus* species, most notably *Acorus tatarinowii* and *Acorus calamus*. It is a research compound that has demonstrated a broad range of pharmacological activities in the central nervous system and metabolic pathways. In China, it is marketed under the brand name Xixinnaojiaonang as an antiepileptic medication. Its mechanism of action is multi-targeted, involving the modulation of GABAergic and glutamatergic neurotransmission, inhibition of voltage-gated sodium channels, and suppression of neuroinflammation through the NF-kappa B pathway. Preclinical studies have also explored its potential as a treatment for depression, anxiety, Parkinson's disease, Alzheimer's disease, and hyperlipidemia, although its clinical utility is currently limited by potential toxicity at higher doses.

Brand names
Xixinnaojiaonang
Other names
α-asarone(E)-asaronetrans-asarone(E)-1-propenyl-2,4,5-trimethoxy-benzene
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA1 (Alpha-1 adrenergic receptor family)GABA-B (Gamma-aminobutyric acid receptor type B)NMDAR (Glutamate receptor ionotropic, NMDA)MAOA (Monoamine oxidase A)NF-κBNaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on alpha-asarone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-asarone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call